Generation Bio(US:GBIO)2025-11-05 21:12Financial Performance - The net loss for Q3 2025 was $5.5 million, or $0.82 per share, a significant improvement from a net loss of $15.3 million, or $2.29 per share, in Q3 2024[5] - Collaboration revenue for Q3 2025 was $1.6 million, a decrease from $7.6 million in Q3 2024, reflecting a decline of approximately 78.8%[12] Cash and Assets - Cash, cash equivalents, and marketable securities decreased to $89.6 million as of September 30, 2025, from $185.2 million as of December 31, 2024, representing a decline of approximately 51.7%[5] - Total assets decreased to $121.9 million as of September 30, 2025, down from $231.2 million as of December 31, 2024, indicating a decline of approximately 47.3%[10] - Total stockholders' equity fell to $50.6 million as of September 30, 2025, compared to $86.2 million as of December 31, 2024, representing a decrease of approximately 41.3%[10] Expenses - Research and development (R&D) expenses increased to $21.7 million for Q3 2025, up from $15.1 million in Q3 2024, reflecting a year-over-year increase of approximately 43.4%[5] - General and administrative (G&A) expenses rose to $12.2 million for Q3 2025, compared to $9.2 million for Q3 2024, marking an increase of approximately 32.6%[5] Strategic Actions - The company recorded a gain on lease termination of $25.5 million following a settlement agreement in August 2025, where it paid $31.0 million to resolve litigation[5] - The company is exploring strategic alternatives to maximize shareholder value, although no assurance is provided regarding the outcome of this process[3] - The company anticipates that its cash resources will fund its operating expenditures for the foreseeable future[5]